These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36230895)

  • 1. Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Sézary Patient-Derived Xenograft Mouse Model.
    Habault J; Thonnart N; Ram-Wolff C; Bagot M; Bensussan A; Poyet JL; Marie-Cardine A
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4
    Habault J; Thonnart N; Pasquereau-Kotula E; Bagot M; Bensussan A; Villoutreix BO; Marie-Cardine A; Poyet JL
    J Invest Dermatol; 2021 Sep; 141(9):2261-2271.e5. PubMed ID: 33745910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
    van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
    Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.
    Poglio S; Prochazkova-Carlotti M; Cherrier F; Gros A; Laharanne E; Pham-Ledard A; Beylot-Barry M; Merlio JP
    Leukemia; 2021 Jun; 35(6):1696-1709. PubMed ID: 33106625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sézary syndrome patient-derived models allow drug selection for personalized therapy.
    Gallardo F; Andrades E; Iglesias A; González J; Solé L; Guillén Y; Blanco G; Colomo L; Gimeno E; Conde D; Rodriguez E; Bielsa-Marso I; Iglesias M; Bellosillo B; Pujol RM; Regueiro JR; Bigas A; Espinosa L
    Blood Adv; 2022 Jun; 6(11):3410-3421. PubMed ID: 35413113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
    Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mouse model for the Sézary syndrome.
    Doebbeling U
    J Exp Clin Cancer Res; 2010 Feb; 29(1):11. PubMed ID: 20149229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
    Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
    van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice.
    Gao J; Ren S; Choonoo G; Chen G; Frleta D; Zhong J; Gupta N; Sharma P; Oyejide A; Atwal GS; Macdonald L; Murphy A; Kuhnert F
    Dis Model Mech; 2023 Oct; 16(10):. PubMed ID: 37718909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imbalanced IL-1B and IL-18 Expression in Sézary Syndrome.
    Manfrere KCG; Torrealba MP; Ferreira FM; de Sousa ESA; Miyashiro D; Teixeira FME; Custódio RWA; Nakaya HI; Ramos YAL; Sotto MN; Woetmann A; Ødum N; Duarte AJDS; Sanches JA; Sato MN
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
    Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
    Front Immunol; 2020; 11():579894. PubMed ID: 33072126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.
    van der Fits L; Out-Luiting JJ; Tensen CP; Zoutman WH; Vermeer MH
    J Invest Dermatol; 2014 Oct; 134(10):2639-2647. PubMed ID: 24756111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.